IAN EDVALSON

Partner
Intellectual Property

EXPERIENCE:

Ian Edvalson is a partner in Wilson Sonsini Goodrich & Rosati's Palo Alto and San Diego offices. He advises numerous domestic and international public and private life sciences and medtech companies, with an emphasis on biopharmaceutical and biotechnology companies, in transactions related to the discovery, development, supply, and commercialization of their products and technologies. He counsels his clients with respect to the structuring and negotiating of a wide range of agreements designed to maximize the value of their assets. 

Ian specializes in working with his clients on the most complex strategic alliances and joint ventures for the development and marketing of all stages of pharmaceutical and other products. In addition, he helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements.

Ian draws on more than 25 years of business and legal experience (including his time leading the corporate and business development functions at Third Wave Technologies, a public genomics company) to address the full range of issues and transactions facing life sciences and medtech companies. He works closely with his clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.

ILLUSTRATIVE REPRESENTATIONS:

  • Armagen in its collaboration with Shire for treatments of Hunter Syndrome
  • Astellas in its joint venture with CVC Investments
  • Biomarin in its joint venture with Sanofi (Genzyme)
  • Caribou Biosciences in its co-founding and licensing of Intellia Therapeutics for therapeutic products based on CRISPR-Cas technologies
  • Caribou Bioscience in its strategic alliance and cross-license with DuPont for CRISPR-Cas technologies and products
  • Charleston Laboratories in its collaboration with Daiichi Sankyo for fixed-dose hydrocodone combination products for OINV in the U.S.
  • Cytopia in its research and license arrangement with Novartis for JAK3 products
  • Durect in its license and asset transfer arrangement with Impax Laboratories for Eladur
  • Durect in its alliance with Santen for a sustained-release SABER ophthalmology product
  • Gilead Sciences in its acquisition of YM Biosciences
  • Gilead Sciences in its license from Theraclone for its broadly neutralizing HIV antibodies
  • Illumina in its license and supply arrangement with Natera for certain diagnostic products and technologies
  • Mesoblast in its strategic alliance with Cephalon (Teva) for mesenchymal precursor cell products for various cardiovascular, CNS, and oncology indications
  • Montigen in its sale to Supergen
  • Mylan in its strategic alliance with Biocon for various biosimilar products
  • Mylan in its strategic alliances with Pfizer for the commercialization of EpiPen, multiple generic products for Japan, and development and commercialization of proprietary inhalable products
  • Pacific Biosystems in its collaboration with F. Hoffman-La Roche for specific diagnostic products and platforms
  • Pain Therapeutics in its collaboration with Durect for extended- and sustained-release opioid products
  • Pfenex in its joint venture with Agila Biotech for various biosimilar products
  • Pfenex in its license and option transaction with Jazz Pharmaceuticals for hematological malignancy products
  • Schiff Nutrition in its acquisition of Ganrden Biotech
  • Shin Nippon Biomedical Laboratories in its license with Transcept for a nasally-delivered DHE product
  • Taiho Pharmaceuticals in its license with PharmaMar for Yondelis
  • Taiho Pharmaceuticals in its license with Teva for Actiq
  • Tolero Pharmaceuticals in its acquisition by Sumitomo Dainippon Pharmaceuticals
  • Tolero in its license from Sanofi for Avocidib
  • Verily Life Sciences in its collaboration with Dexcom for miniature continuous blood glucose monitoring devices
  • Y’s Therapeutics in its acquisition of certain assets from Thios Pharmaceuticals
  • Zymeworks in its strategic alliances with Celgene, Eli Lilly, Glaxo SmithKline, and Merck to design, develop, and commercialize proprietary bi-specific antibodies
EDUCATION:
  • J.D., University of Chicago Law School
  • B.S. & B.A., Molecular Biology & Korean, Brigham Young University
HONORS:
SELECT SPEAKING ENGAGEMENTS:
  • Panelist, “Building Successful Corporate Partnerships,” HealthTech Conference, Santa Clara Convention Center, October 27, 2015
  • Speaker, “The Challenges of Pharma and Biotech in Emerging Markets—Focus on China and India,” AusBiotech National Conference, October 2014
  • Speaker, “Where does Biopharma go from here?” EPPIC Annual Conference, January 9, 2011
  • Panelist, “Licensing Strategies—Views from the Trenches,” The Bio2Device Group, September 2010
ADMISSIONS:
  • State Bar of California

Contact Information

650 Page Mill Road
Palo Alto, CA 94304
Phone | 650-849-3395
Fax | 650-493-6811

12235 El Camino Real
Suite 200
San Diego, CA 92130
Phone | 858-350-2300
Fax | 858-350-2399

Email | Ian Edvalsoniedvalson@wsgr.com


Areas of Expertise

Print to PDF